← FDA Drug Approvals (Drugs@FDA)
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MYLAN · Approved 2024-09-05
Drug application
- FDA Application #
ANDA209061- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
- Generic name
- Efavirenz
- Active ingredients
- EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Discontinued
- Sponsor
- MYLAN
- First approval
- 2024-09-05
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown